OneMedForum 2009: Finance Conference for Emerging Med Tech Companies

The OneMedPlace finance conference for emerging med tech companies, the OneMedForum, will be held January 13-14 in San Francisco. Click here to learn more. San Francisco, in early January, is the place to be if you’re in the healthcare industry. Thousands of industry executives and investors will be...

Escalon: Expansion Efforts Impact Gross Margins

Escalon Medical managed solid revenue growth its first fiscal quarter of 2009. The company reported quarterly revenues of $8.7 million, compared with $6.9 million in the same period last year. The increase was primarily due to the acquisition of JAS Diagnostics in June. Escalon operates through several...

[Video Profile] Interview with Eric Le Royer, CEO of EndoSense SA

Endosense is developing a catheter ablation treatment for cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than six million people worldwide. Currently, most AF patients are treated with ineffective and side effect-causing...

Endologix Rejects Elliott Associates Buyout Bid

Regular Sentinel readers know I’m a fan of Endologix. The developer of a minimally invasive treatment for abdominal aortic aneurysms has had a slate of positive news of late. In addition to two new FDA clearances, in its third quarter, the company significantly improved its liquidity position and is on...

Endocare and Galil Medical to Merge

Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical have agreed to merge. The combined company will be focused on the development of cryoablation technologies, a minimally invasive method to freeze and destroy cancerous...

Abiomed: Record Revenue Driven by Impella

In June, Abiomed got the green light from the FDA to market its Impella 2.5 CAD, a minimally invasive ventricular assist device. At the time, I reported that the company could potentially double its revenues on sales of this device alone. In its most recent quarter, revenues grew 75% to $20.0 million, up...

[Video Interview] Richard Taney, President & CEO of Delcath Systems

One of the central problems in using chemotherapy to treat cancer is its harmful effect on organ health. Lower dosages of the drug are often used to limit side effects, which may diminish benefits of the therapy. Delcath Systems has developed a drug delivery system that isolates the liver from the...

Cyberkinetics Neurotechnology Nearing Paralysis

In a recent filing, Cyberkinetics Neurotechnology said it only had enough cash to last 30 days. If negotiations fail with its secured creditor, GE Capital, the company will shut down and may seek bankruptcy protection. At one time an oft-discussed early stage device firm, Cyberkinetics has seen a steady...